Tue, March 5, 2024

Eliana Merle Maintained (AKRO) at Strong Buy with Increased Target to $42 on, Mar 5th, 2024

Eliana Merle of UBS, Maintained "Akero Therapeutics, Inc." (AKRO) at Strong Buy with Increased Target from $39 to $42 on, Mar 5th, 2024.

Eliana, nor any peers, have made any analyst calls on AKRO in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30